Maaike C Zuur-Telgen1, Marjolein G J Brusse-Keizer2, Paul D L P M VanderValk2, Job van der Palen3, Huib A M Kerstjens4, M G Ron Hendrix5. 1. Department of Pulmonary Medicine, Medisch Spectrum Twente, Enschede; Department of Internal Medicine, Medisch Spectrum Twente, Enschede. Electronic address: maaiketelgen@gmail.com. 2. Department of Pulmonary Medicine, Medisch Spectrum Twente, Enschede. 3. Department of Pulmonary Medicine, Medisch Spectrum Twente, Enschede; Department of Pulmonary Medicine University Medical Centre Groningen, University of Groningen, Groningen. 4. Department of Research Methodology, Measurement, and Data Analysis, University of Twente, Enschede; Groningen Research Institute for Asthma and COPD (GRIAC), Groningen, The Netherlands. 5. Regional Laboratory of Public Health, University of Twente, Enschede; Department of Medical Microbiology, University Medical Centre Groningen, University of Groningen, Groningen.
Abstract
BACKGROUND: Midrange-proadrenomedullin (MR-proADM) has been shown to be elevated in patients hospitalized for an acute exacerbation of COPD (AECOPD) and in patients with community-acquired pneumonia. When measured during AECOPDs, MR-proADM has also been shown to be a predictor of mortality. We hypothesized that MR-proADM levels measured in a stable state could also predict mortality. METHODS: We included 181 patients in whom we had paired plasma samples for MR-proADM determinations during a stable state and at hospitalization for an AECOPD when they also produced sputum. Time to death or censoring was compared between patients with MR-proADM above or below the median of 0.71 nmol/L. The predictive value of MR-proADM for survival was determined by calculating the C statistic. RESULTS: Patients with COPD and MR-proADM levels > 0.71 nmol/L in the stable state had a threefold-higher risk of dying than did patients with MR-proADM levels < 0.71 nmol/L (hazard ratio, 2.98 [95% CI, 1.51-5.90]; C statistic, 0.76). The corrected OR for 1-year mortality was 8.90 (95% CI, 1.94-44.6) in patients with high MR-proADM levels measured in the stable state, compared with patients with low levels measured in the stable state. CONCLUSIONS: MR-proADM measured in the stable state appeared to be a strong predictor of mortality in patients with COPD. MR-proADM is far easier to measure than other predictors of mortality in COPD, such as BMI, airflow obstruction, dyspnea, and exercise capacity score.
BACKGROUND: Midrange-proadrenomedullin (MR-proADM) has been shown to be elevated in patients hospitalized for an acute exacerbation of COPD (AECOPD) and in patients with community-acquired pneumonia. When measured during AECOPDs, MR-proADM has also been shown to be a predictor of mortality. We hypothesized that MR-proADM levels measured in a stable state could also predict mortality. METHODS: We included 181 patients in whom we had paired plasma samples for MR-proADM determinations during a stable state and at hospitalization for an AECOPD when they also produced sputum. Time to death or censoring was compared between patients with MR-proADM above or below the median of 0.71 nmol/L. The predictive value of MR-proADM for survival was determined by calculating the C statistic. RESULTS:Patients with COPD and MR-proADM levels > 0.71 nmol/L in the stable state had a threefold-higher risk of dying than did patients with MR-proADM levels < 0.71 nmol/L (hazard ratio, 2.98 [95% CI, 1.51-5.90]; C statistic, 0.76). The corrected OR for 1-year mortality was 8.90 (95% CI, 1.94-44.6) in patients with high MR-proADM levels measured in the stable state, compared with patients with low levels measured in the stable state. CONCLUSIONS:MR-proADM measured in the stable state appeared to be a strong predictor of mortality in patients with COPD. MR-proADM is far easier to measure than other predictors of mortality in COPD, such as BMI, airflow obstruction, dyspnea, and exercise capacity score.
Authors: Emanuel Citgez; Job van der Palen; Kirsten Koehorst-Ter Huurne; Kris Movig; Paul van der Valk; Marjolein Brusse-Keizer Journal: BMJ Open Respir Res Date: 2016-06-17
Authors: Lucas Boeck; Joan B Soriano; Marjolein Brusse-Keizer; Francesco Blasi; Konstantinos Kostikas; Wim Boersma; Branislava Milenkovic; Renaud Louis; Alicia Lacoma; Remco Djamin; Joachim Aerts; Antoni Torres; Gernot Rohde; Tobias Welte; Pablo Martinez-Camblor; Janko Rakic; Andreas Scherr; Michael Koller; Job van der Palen; Jose M Marin; Inmaculada Alfageme; Pere Almagro; Ciro Casanova; Cristobal Esteban; Juan J Soler-Cataluña; Juan P de-Torres; Marc Miravitlles; Bartolome R Celli; Michael Tamm; Daiana Stolz Journal: Eur Respir J Date: 2016-04-21 Impact factor: 16.671
Authors: Sara Graziadio; Rachel Amie O'Leary; Deborah D Stocken; Michael Power; A Joy Allen; A John Simpson; David Ashley Price Journal: BMJ Open Date: 2019-02-22 Impact factor: 2.692